title: Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.
authors.affiliation: Intensive Care Unit, Centre Hospitalier Intercommunal Poissy Saint Germain en Laye, Poissy, France.
authors.forename: Mikael
authors.initials: M
authors.lastname: Alves
authors.affiliation: Emergency Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Laurène
authors.initials: L
authors.lastname: Janneau-Magrino
authors.affiliation: Emergency Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Legendre
authors.affiliation: Emergency Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France; Faculté de Médecine, Université Pierre et Marie Curie, Paris, France. Electronic address: dominique.pateron@sat.aphp.fr.
authors.forename: Dominique
authors.initials: D
authors.lastname: Pateron
authors.affiliation: Faculté de Médecine, Université Pierre et Marie Curie, Paris, France; Intensive Care Unit, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Guidet
authors.affiliation: Emergency Department, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Youri
authors.initials: Y
authors.lastname: Yordanov
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D001714:Bipolar Disorder / Q000150:complications; D065692:Cytochrome P-450 CYP3A Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D004087:Dihydroergotamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004881:Ergotism / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000150:complications / Q000188:drug therapy*; D019259:Lamivudine / Q000008:administration & dosage; D061466:Lopinavir / Q000008:administration & dosage; D056990:Post-Exposure Prophylaxis / Q000379:methods*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D015215:Zidovudine / Q000008:administration & dosage
chemical_list: D000998:Antiviral Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D014662:Vasoconstrictor Agents; D061466:Lopinavir; D019259:Lamivudine; D004087:Dihydroergotamine; D015215:Zidovudine; D019438:Ritonavir